^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NBL-020

    i
    Other names: NBL-020
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    TNFRSF1B antagonist
    Related drugs:
    Associations

    News

    Trials
    almost2years
    A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=200, Recruiting, NovaRock Biotherapeutics, Ltd | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Apr 2025 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    NBL-020
    over2years
    A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=200, Recruiting, NovaRock Biotherapeutics, Ltd | Not yet recruiting --> Recruiting | Initiation date: May 2023 --> Aug 2023
    Enrollment open • Trial initiation date • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    NBL-020
    almost3years
    A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors. (clinicaltrials.gov)
    P1, N=200, Not yet recruiting, NovaRock Biotherapeutics, Ltd
    New P1 trial • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    NBL-020